LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
122.00
+2.10 (+1.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close119.90
Open123.20
Bid102.50 x 1000
Ask125.20 x 800
Day's Range120.62 - 124.96
52 Week Range57.24 - 124.97
Volume343,607
Avg. Volume527,965
Market Cap1.958B
Beta (5Y Monthly)1.39
PE Ratio (TTM)4.31
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 02, 2010
1y Target EstN/A
All
News
Press Releases
  • Ligand CEO Issues Letter to Captisol Customers
    Business Wire

    Ligand CEO Issues Letter to Captisol Customers

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The full text of that letter is as follows:

  • Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
    Business Wire

    Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new program incorporates Icagen’s ion channel technology and expertise and is directed at a specific novel ion channel target relevant to neurodegenerative disease. The new program is in addition to ongoing work on another novel CNS target.

  • Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
    Business Wire

    Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors. The milestone payment will consist of $2 million in cash and $1 million in Palvella Series C Preferred Stock.

  • GlobeNewswire

    Palvella Therapeutics Completes $45 Million Series C Financing

    Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and.

  • Ligand Reports First Quarter 2020 Financial Results
    Business Wire

    Ligand Reports First Quarter 2020 Financial Results

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.

  • Ligand’s First Quarter Financial Results to be Reported May 6th
    Business Wire

    Ligand’s First Quarter Financial Results to be Reported May 6th

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report first quarter 2020 financial results on May 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

  • ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery
    CNW Group

    ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery

    VICTORIA , April 17, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to provide an update on its research activities for the novel coronavirus (SARS-CoV-2) which outlines the Company's workflows for their experimental vaccines and therapeutics for the research community. Hence, IPA anticipates that it can accelerate anti-SARS-CoV-2 human antibody discovery, targeting multiple viral epitopes and mechanisms of viral evasion, by immunizing Ligand's (LGND) OmniRat® animals using the Company's Rapid Prime™ protocol followed by IPA's B cell Select™ and hybridoma generation in parallel with human, naive phage library screening.

  • Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
    Business Wire

    Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provides a general corporate update, as follows:

  • Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
    Business Wire

    Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations. As previously announced, the purchase price was $15 million in cash, and Icagen is entitled to receive additional cash payments based on certain revenue achievements.

  • Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com
    Business Wire

    Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that today’s scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured. The webcast will take place as previously scheduled at 2:35 p.m. ET and is available here. Conference one-on-one investor meetings have been moved to telephone calls, and the new slides Ligand will be using during those meetings have been posted to www.ligand.com.

  • Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
    Business Wire

    Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March

    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at two upcoming investor conferences.

  • GlobeNewswire

    INVESTOR ALERT: BDX LGND LOPE SBT: Kirby McInerney LLP Continues Investigation of Shareholder Claims

    NEW YORK, Feb. 19, 2020 -- The law firm of Kirby McInerney LLP is investigating whether the following publicly-traded companies have violated federal securities laws and/or.

  • Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals
    CNW Group

    Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA , Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned subsidiary, has entered into a worldwide OmniAb® platform license agreement with Ligand Pharmaceuticals (LGND). This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities. Under the license, Talem has the right to develop and partner fully human antibodies in OmniRat®, OmniFlic®, OmniMouse®, OmniChicken®, and OmniClic™.

  • ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom
    CNW Group

    ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

    VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.

  • GlobeNewswire

    Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

    Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.

  • PR Newswire

    Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP

    Short position in Ligand pharmaceuticals, long position in Geospace Technologies, contribute to 70.27 percent net return in 1H, 2019 SHELBURNE, Vt ., July 16, 2019 /PRNewswire/ -- Lemelson Capital Management, ...

  • Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
    PR Newswire

    Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

    SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure. The smaller delivery volume enables use of established drug container and device technology developed for insulin and other biologics, resulting in faster development and reduced cost. SQ Innovation to use advanced 3 mL drug delivery platform by Sensile Medical AG, a Gerresheimer company, for the novel treatment.